For 2023, we highlight two important research areas for the group. Firstly, in collaboration with Dr. Victor Puntes, we have achieved the successful development of antioxidant, anti-inflammatory, and antio-angiogenic eye drops, formulated with cerium oxide nanoparticles. These eye drops exhibit potential in treating both wet and dry forms of age-related macular degeneration. We patented the formulation and signed a license option agreement with a biomedical company to advance its development and commercialization.
Secondly, over the last few years, our group has been working with the Mathematics Department at the University of La Rioja and family doctors from ICS, particularly Dr. Josep Vidal, to develop AI tools for ophthalmic pathology, detecting retinal diseases using non-mydriatic camera images. Currently, our projects extend to utilizing AI for telemedicine visits via phone bots, managing childhood myopia, and forecasting corneal complications linked to cataract surgery.
eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Chronic, Prevalent Diseases & Aging
- Woman & Child Health & Rare Diseases
Team
Group Leader
José García Arumí
Principal Investigator (PI)
Anna Duarri, Anna Boixadera Espax, Miguel Angel Zapata Victori, Miguel Ángel Arcediano
PhD Students
Maddalen Zufiaurre Seijo, Helena Isla Magrané, Laura Natalia Distefano
Lab Technicians
Alfredo Pueyo Ferrer, Marta Garrido Marin, Eric Kirkegaard Biosca, Jorge Fernandez Engroba, Helena Brosa Morros, Jaume Rigo Quera, Alba Gil Loyo, Pere Marc Almagro Muriana, Ferran Casals Riera, Gemma Gervilla Diaz, Lidia Martin Firvida, Mariona Fons i Castells
Nursing and Technical Staff
Mireia Campius Piñas
Publications
Salas A, Badia A, Fontrodona L, Zapata M, García-Arumí J, Duarri A
Dysfunction in the Laser-Induced Choroidal Neovascularization Mouse Model.
Biomedicines. 2023 Sep 2;11(9):2445
DOI: 10.3390/biomedicines11092445
IF: 6.081
Bogdanov P, Duarri A, Sabater D, Salas A, Isla-Magrané H, Ramos H, Huerta J, Valeri M, García-Arumí J, Simó R, Hernández C
Blocking Hemopexin With Specific Antibodies: A New Strategy for Treating Diabetic Retinopathy
Diabetes. 2023 Dec 1;72(12):1841-1852
DOI: 10.2337/db23-0027
IF: 9.461
Zufiaurre-Seijo M, García-Arumí J, Duarri A
Clinical and Molecular Aspects of C2orf71/PCARE in Retinal Diseases
Int J Mol Sci. 2023 Jun 26;24(13):10670
DOI: 10.3390/ijms241310670
IF: 5.924
Badia A, Duarri A, Salas A, Rosell J, Ramis J, Gusta MF, Casals E, Zapata MA, Puntes V, García-Arumí J
Repeated Topical Administration of 3 nm Cerium Oxide Nanoparticles Reverts Disease Atrophic Phenotype and Arrests Neovascular Degeneration in AMD Mouse Models
ACS Nano 2023, 17, 2, 910–926
DOI: 10.1021/acsnano.2c05447
IF: 15.881
Danese C, Kale AU, Aslam T, Lanzetta P, Barratt J, Chou YB, Eldem B, Eter N, Gale R, Korobelnik JF, Kozak I, Li X, Li X, Loewenstein A, Ruamviboonsuk P, Sakamoto T, Ting DSW, van Wijngaarden P, Waldstein SM, Wong D, Wu L, Zapata MA, Zarranz-Ventura J
The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus
Curr Opin Ophthalmol. 2023 Sep 1;34(5):396-402
DOI: 10.1097/ICU.0000000000000980
IF: 3.761
Projects
RETVISION: From molecular genetic diagnosis to advanced therapies to treat retinal degenerative diseases
Principal Investigator: Josep García Arumí
Agency: Instituto de Salud Carlos III
Funding: 123,420 €
Period: 2023 – 2025
Análisis masivo de datos de bioimagen para el desarrollo de terapias celulares para enfermedades degenerativas de la retina (Digital Retina)
Principal Investigator: Miguel Ángel Zapata
Agency: MINISTERIO DE CIENCIA, INNOVACIÓN y UNIVERSIDADES
Funding: 188,760 €
Period: 2022 – 2025
Red de Enfermedades Inflamatorias (RICORS).
Principal Investigator: Josep García Arumí
Agency: Instituto de Salud Carlos III
Funding: 141,350 €
Period: 2022 – 2024
CeO2 Nanoparticles-assisted stem cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases (CELLUX)
Principal Investigator: Anna Duarri
Agency: Euronanomed III - Instituto de Salud Carlos III
Funding: 174,845€
Period: 2020 – 2024
Terapia génica para la retinosis pigmentaria: prueba de concepto para el gen EYS (EYeStherapy).
Principal Investigator: Josep García Arumí, Anna Duarri
Agency: AYUDAS A LA INVESTIGACIÓN EN VISIÓN – ONCE
Funding: 20,000 €
Period: 2022-2023
Patents
OPHTHALMIC TOPICAL COMPOSITION WITH CERIA NANOPARTICLES FOR TREATING DISEASES OF POSTERIOR SEGMENT OF THE EYE
Priority Number: PCT/EP2022/059891
Priority Date: 15/04/2021
Applicants: 77.5% VHIR, 15% ICREA, 7.5% ICN2
Solución coloreada, en particular, para su uso en métodos quirúrgicos para el tratamiento de los cuerpos humanos o animales
Priority Number: EP2827911
Priority Date: 12/03/2013
Applicants: AL.CHI.MI.A. S.R.L
